Virology

Regimen

Antiretroviral therapy

Efavirenz

Internal medicine

Viral load

Dolutegravir

Human immunodeficiency virus (HIV)

Medicine

New England Journal of Medicine

An efavirenz-based regimen (with a 600-mg dose of efavirenz, known as EFV600) was the World Health Organization preferred first-line treatment for human immunodeficiency virus type 1 (HIV-1) infection until June 2018. Given concerns about side effects, dolutegravir-based and low-dose efavirenz–based combinations have been considered as first-line treatments for HIV-1 in resource-limited settings.

Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1